FPIN's Clinical Inquiries

Effective Therapies for Intermittent Claudication



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2011 Sep 15;84(6):699-704.

Clinical Question

What therapies are effective for treating intermittent claudication?

Evidence-Based Answer

Supervised exercise programs are recommended to produce clinically significant improvements in walking distance in patients with stable intermittent claudication. (Strength of Recommendation [SOR]: A, based on systematic reviews of randomized controlled trials [RCTs].) Antiplatelet agents, statins, and pentoxifylline (Trental) can be prescribed to patients with claudication to improve walking distance. (SOR: B, based on systematic reviews of low-quality RCTs.) In most patients, percutaneous transluminal angioplasty (PTA) generally is not recommended. (SOR: B, based on systematic reviews of low-quality RCTs.) Direct comparison of effective therapies is not possible because of heterogeneous study populations and outcome measures.

Evidence Summary

The studies evaluating the effectiveness of therapies for intermittent claudication symptoms included patients with various degrees of claudication and used heterogeneous outcome measures and statistical analyses, which precluded direct comparison. The claudication outcomes studied were initial claudication distance (i.e., the distance a patient can walk before the onset of claudication pain), absolute claudication distance (i.e., the distance a patient has walked when claudication pain prevents further walking), and maximal walking distance (i.e., the total distance walked, including stops to rest and recover). Therapies and outcome measures are listed in Table 1.1,2

Table 1:

Therapies for Intermittent Claudication and Associated Patient Outcomes

Therapy* No. of RCTs (patients) Net increase in maximal walking distance No. of RCTs (patients) Net increase in initial claudication distance

Exercise1,2

Nine (656)

156 m (512 ft)† 95% CI, 81 to 231 m (266 to 758 ft)

Five (151)

139 m (456 ft) 95% CI, 31 to 247 m (102 to 810 ft)

Antiplatelet agents1

Five (1,077)

59 m (194 ft) 95% CI, 37 to 81 m (121 to 266 ft)

Statins1

Two (146)

104 m (341 ft) 95% CI, 62 to 147 m (203 to 482 ft)

One (354)

No difference

PTA1

One (62)

–260 m (–853 ft; shorter distance than medical therapy)

Two (98)

0 to 495 m (1,624 ft)‡

Cilostazol (Pletal)1

Seven (1,579)

50 m (164 ft) 95% CI, 24 to 75 m (79 to 246 ft)

Six (1,326)

31 m (102 ft) 95% CI, 21 to 41 m (69 to 135 ft)

Pentoxifylline (Trental)1

Six (788)

59 m (194 ft) 95% CI, 37 to 81 m

One (471)

No difference or deterioration


note: Most studies reported only the net difference in walking distance between therapy and placebo groups. Direct comparison of therapies was not possible because of heterogeneous patient populations.

CI = confidence interval; PTA = percutaneous transluminal angioplasty; RCT = randomized controlled trial.

*—Therapies listed in order from most to least effective.

†—Corresponds to an increase in walking distance from baseline of 50 to 200 percent.

‡—Temporary improvement only; no difference at two years.

Information from references 1 and 2.

Table 1:   Therapies for Intermittent Claudication and Associated Patient Outcomes

View Table

Table 1:

Therapies for Intermittent Claudication and Associated Patient Outcomes

Therapy* No. of RCTs (patients) Net increase in maximal walking distance No. of RCTs (patients) Net increase in initial claudication distance

Exercise1,2

Nine (656)

156 m (512 ft)† 95% CI, 81 to 231 m (266 to 758 ft)

Five (151)

139 m (456 ft) 95% CI, 31 to 247 m (102 to 810 ft)

Antiplatelet agents1

Five (1,077)

59 m (194 ft) 95% CI, 37 to 81 m (121 to 266 ft)

Statins1

Two (146)

104 m (341 ft) 95% CI, 62 to 147 m (203 to 482 ft)

One (354)

No difference

PTA1

One (62)

–260 m (–853 ft; shorter distance than medical therapy)

Two (98)

0 to 495 m (1,624 ft)‡

Cilostazol (Pletal)1

Seven (1,579)

50 m (164 ft) 95% CI, 24 to 75 m (79 to 246 ft)

Six (1,326)

31 m (102 ft) 95% CI, 21 to 41 m (69 to 135 ft)

Pentoxifylline (Trental)1

Six (788)

59 m (194 ft) 95% CI, 37 to 81 m

One (471)

No difference or deterioration


note: Most studies reported only the net difference in walking distance between therapy and placebo groups. Direct comparison of therapies was not possible because of heterogeneous patient populations.

CI = confidence interval; PTA = percutaneous transluminal angioplasty; RCT = randomized controlled trial.

*—Therapies listed in order from most to least effective.

†—Corresponds to an increase in walking distance from baseline of 50 to 200 percent.

‡—Temporary improvement only; no difference at two years.

Information from references 1 and 2.

EXERCISE PROGRAMS

The studies in two systematic reviews evaluated the effects of exercise in patients with stable chronic intermittent claudication who were randomized to participate in exercise programs or to receive usual care for periods of three to 24 months.1,2 The types of exercise included supervised sessions of strength training, pole striding (walking up an incline using modified ski poles), or upper or lower limb exercises. Programs lasted at least 30 to 40 minutes twice per week. In one systematic review, exercise improved walking time on a treadmill by about five minutes more than usual care, and produced improvements of 50 to 200 percent beyond baseline walking distances.2 Upper and lower limb exercises produced equivalent improvements. A third systematic review of eight RCTs (n = 319) found that supervised exercise improved walking distance by approximately 150 m (492 ft) compared with unsupervised exercise over three to 12 months.3

ANTIPLATELET AGENTS

Five RCTs in a systematic review (n = 1,077) evaluated the effects of antiplatelet therapy in patients with moderate intermittent claudication who took an antiplatelet agent over a five-to 12-month period.1 The results showed a 59-m (194-ft) increase in maximal walking distance (95% confidence interval, 37 to 81 m [121 to 266 ft]). Cilostazol (Pletal) at a dosage of 100 mg twice per day produced greater improvement than placebo at six to 24 weeks, but a dosage of 50 or 150 mg twice per day produced similar benefit. Cilostazol commonly led to adverse effects, including headache, diarrhea, and palpitations.1

STATINS

Two RCTs found that simvastatin (Zocor) improved maximal walking distance in patients with claudication, but the studies were statistically heterogeneous. A third RCT found that 80 mg of atorvastatin (Lipitor) per day improved initial claudication time by 40 seconds over 12 months but did not improve maximal walking time.1

PENTOXIFYLLINE

A systematic review of six RCTs found that pentoxifylline use improves maximal walking distances more than placebo. However, a large RCT found that pentoxifylline use did not change or worsen initial claudication distance.1

PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY

One of two RCTs in a systematic review evaluating PTA in patients with mild to moderate claudication symptoms found short-term improvement, whereas the other RCT did not. Another RCT found that optimal medical therapy alone was superior to PTA plus medical therapy at two years. Low-quality and very low-quality RCTs found that routinely adding a stent to PTA produced greater maximal walking distance at 12 months than PTA alone.1

PROSTAGLANDIN E1

A systematic review (five very low-quality RCTs, n = 400) found that intravascular prostaglandins are unlikely to improve symptoms in patients with intermittent claudication. Prostaglandins also are associated with high rates of adverse effects, such as headache, vasodilation, diarrhea, and tachycardia.1

TREATMENTS WITH INCONCLUSIVE RESULTS

Ginkgo extract (11 RCTs, n = 477), vitamin E (five RCTs, n = 265), omega-3 fatty acids (six RCTs, n = 313), and anticoagulants (heparin, low-molecular-weight heparin, and oral anticoagulants) did not improve symptoms in patients with intermittent claudication.47

Recommendations from Others

The Eighth American College of Chest Physicians Conference on Antithrombotic and Thrombolytic Therapy recommends lifelong use of aspirin at a dosage of 75 to 100 mg per day in all patients with intermittent claudication. Clopidogrel (Plavix) is recommended in patients who cannot take aspirin. Cilostazol is recommended only in patients with disabling intermittent claudication who do not respond to risk factor modification and exercise, and who are not surgical candidates. The guidelines also recommend against the use of pentoxifylline, prostaglandins, and anticoagulants in patients with intermittent claudication.8

The American College of Cardiology/American Heart Association 2005 guidelines for the management of peripheral arterial disease recommend statins, antiplatelet therapy, risk factor modification, and supervised exercise training (30 to 45 minutes at least three times per week) for all patients with peripheral arterial disease. They recommend a trial of cilostazol for patients with lifestyle-limiting claudication. They also recommend surgical interventions in persons with functional disability from claudication symptoms that are unresponsive to exercise or pharmacotherapy but that have a reasonable likelihood of improvement.9

Address correspondence to Heather M. Rudisill, MD, at heather_rudisill@valleymed.org. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.


Copyright Family Physicians Inquiries Network. Used with permission.

REFERENCES

1. Cassar K. Peripheral arterial disease. January 11, 2011. http://www.clinicalevidence.bmj.com/ceweb/pmc/2011/01/0211 (subscription required). Accessed April 21, 2011.

2. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008;(4):CD000990.

3. Bendermacher BL, Willigendael EM, Teijink JA, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006;(2):CD005263.

4. Nicolaï SP, Kruidenier LM, Bendermacher BL, Prins MH, Teijink JA. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2009;(2):CD006888.

5. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev. 2000;(2):CD000987.

6. Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev. 2007;(4):CD003833.

7. Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev. 2001;(3):CD001999.

8. Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):815S–843S.

9. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47(6):1239–1312.

Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (http://www.cebm.net/?o=1025).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to http://www.fpin.org or e-mail: questions@fpin.org.

A collection of FPIN's Clinical Inquiries published in AFP is available at http://www.aafp.org/afp/fpin.


Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article